Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
After finishing at $129.74 in the prior trading day, Transmedics Group Inc (NASDAQ: TMDX) closed at $127.55, down -1.69%. In other words, the price has decreased by -$1.69 from its previous closing price. On the day, 0.6 million shares were traded. TMDX stock price reached its highest trading level at $130.0163 during the session, while it also had its lowest trading level at $126.2432.
Ratios:
Our goal is to gain a better understanding of TMDX by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 10.86 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 250.62. For the most recent quarter (mrq), Quick Ratio is recorded 9.17 and its Current Ratio is at 9.86. In the meantime, Its Debt-to-Equity ratio is 1.63 whereas as Long-Term Debt/Eq ratio is at 1.62.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on December 17, 2024, Downgraded its rating to Neutral and sets its target price to $75 from $116 previously.
Oppenheimer reiterated its Outperform rating for the stock on October 29, 2024, while the target price for the stock was revised from $200 to $125.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 06 ’25 when Hassanein Waleed H bought 8,400 shares for $118.68 per share. The transaction valued at 996,912 led to the insider holds 477,759 shares of the business.
Hassanein Waleed H bought 8,475 shares of TMDX for $985,209 on Aug 07 ’25. The President & CEO now owns 486,234 shares after completing the transaction at $116.25 per share. On Aug 04 ’25, another insider, Basile Edward M, who serves as the Director of the company, sold 4,143 shares for $125.51 each. As a result, the insider received 519,988 and left with 2,866 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TMDX now has a Market Capitalization of 4348230656 and an Enterprise Value of 4466471936. As of this moment, Transmedics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 65.96, and their Forward P/E ratio for the next fiscal year is 46.71. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.25. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.18 while its Price-to-Book (P/B) ratio in mrq is 13.65. Its current Enterprise Value per Revenue stands at 8.407 whereas that against EBITDA is 44.53.
Stock Price History:
The Beta on a monthly basis for TMDX is 2.18, which has changed by -0.2365247 over the last 52 weeks, in comparison to a change of 0.15005577 over the same period for the S&P500. Over the past 52 weeks, TMDX has reached a high of $177.37, while it has fallen to a 52-week low of $55.00. The 50-Day Moving Average of the stock is 2.78%, while the 200-Day Moving Average is calculated to be 39.49%.
Shares Statistics:
The stock has traded on average 1.00M shares per day over the past 3-months and 1161410 shares per day over the last 10 days, according to various share statistics. A total of 34.04M shares are outstanding, with a floating share count of 32.83M. Insiders hold about 3.69% of the company’s shares, while institutions hold 109.02% stake in the company. Shares short for TMDX as of 1753920000 were 7669931 with a Short Ratio of 7.64, compared to 1751241600 on 8044092. Therefore, it implies a Short% of Shares Outstanding of 7669931 and a Short% of Float of 38.66.
